Avvio Medical, Inc.

Avvio Medical, Inc. is a clinical-stage medical technology company based in San Francisco, California. The company focuses on improving the treatment of urinary stone disease, particularly kidney stones, by offering innovative and minimally invasive solutions. Their flagship product, the AVVIO Acoustic Cavitation Lithotripsy System, utilizes low-pressure ultrasound waves to fragment urinary stones, potentially eliminating the need for anesthesia and X-ray imaging in many cases. This technology allows for effective outpatient procedures, enhancing patient experiences and reducing medical costs. Avvio Medical's system specifically targets 5-15 millimeter kidney stones, which typically require more invasive treatments. By enabling urologists to perform procedures without general anesthesia or expensive equipment, the company provides significant clinical and economic benefits for both patients and healthcare providers. Avvio Medical is ISO 13485:2016 certified, demonstrating its commitment to quality and regulatory compliance. Led by CEO Paul Molloy, the company’s experienced team is dedicated to advancing MedTech innovation and improving patient outcomes in kidney stone treatment.

• Employees 30
• Founded 2014
• Annual Revenue $4000000
• Total Funding $25504932